Engineered T Cell Engagers for Precision, Depth, and Safety
Artemia's platform leverages high-affinity binding and tuned kinetics to overcome the limitations of first-generation engagers. By optimizing the therapeutic window, we enable potent immune cell activation while minimizing off-target toxicity.
Core Design Principles
Our platform is designed to translate the clinical promise of cellular therapies into scalable, off-the-shelf immunotherapies for outpatient use
Tuned CD3 Engagment
Optimizes T cell activation kinetics
Expands therapeutic window
Deep Immune Cell Depletion
(Autoimmunity)
Targets multiple immune cell subsets
Enables deep immune reset
Multi-Antigen Targeting
(Oncology)
Engagement of multiple tumor antigens
Mitigates tumor escape
From Design to Therapeutic Impact
Translating clinical promise into scalable immunotherapies
Deeper Immune Reset
Improved Safety Window
More complete elimination of disease-driving cells.
Controlled T cell activation reduces toxicity risk.
Durable Responses
Sustained efficacy across autoimmune and oncology settings.
Scalable Delivery Model
Cost-effective, off-the-shelf biologics for outpatient use.